In this study, we show that murine pancreatic tumours driven by activated Kras and Pten deficiency are highly sensitive to mTOR inhibition, by contrast with tumours driven by activated Kras and mutation of Trp53, demonstrating that the therapeutic ‘phenotype’ is dependent on the genotype of tumours. This evidence concerns the gene MTOR and pancreatic neoplasm.